Faculty, Staff and Student Publications
Publication Date
9-16-2022
Journal
Medicine
DOI
10.1097/MD.0000000000030608
PMID
36123927
PMCID
PMC9478288
PubMedCentral® Posted Date
9-16-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic malignancies and/or hematopoietic cell transplants (HCT). Patients in our center were simultaneously screened using serological (anti-HCV) and molecular (HCV RNA) assays (February 2019-November 2019). In total, 214 patients were enrolled in this study. Three patients (1.4%) were positive for anti-HCV, and 2 (0.9%) were positive for HCV RNA. The overall percentage agreement was 99.5% (95% CI: 97.4-99.9). There were no cases of seronegative HCV virus infection. The positive percentage agreement was 66.7% (95% CI: 20.8-93.9), and the negative percentage agreement was 100.0% (95% CI: 98.2-100.0). Cohen kappa coefficient was 0.80 (95% CI: 0.41-1.00, P < .0001). The diagnostic yield of screening for chronic HCV infection in patients with cancer is similar for serologic and molecular testing.
Keywords
Hematologic Neoplasms, Hepacivirus, Hepatitis C, Humans, Molecular Diagnostic Techniques, RNA
Published Open-Access
yes
Recommended Citation
Torres, Harrys A; Angelidakis, Georgios; Jiang, Ying; et al., "Serologic Versus Molecular Testing for Screening for Hepatitis C Virus Infection in Patients With Hematologic Malignancies" (2022). Faculty, Staff and Student Publications. 4924.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4924
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons